Chronological Changes of Lower Urinary Tract Symptoms in Elderly Patients with Prostate Cancer after Low-Dose-Rate Prostate Brachytherapy
暂无分享,去创建一个
M. Matsuo | M. Nakano | Daiki Kato | Makoto Kawase | Manabu Takai | T. Koie | Y. Tobisawa | Takayasu Ito | T. Kumano | K. Nakane | Hirota Takano | T. Mori | K. Iinuma | Kunihiro Tsuchiya | H. Takano
[1] M. Nakano,et al. Patient age as a predictive factor in biochemical recurrence following brachytherapy: Oncological outcomes at a single center , 2022, Prostate international.
[2] K. Amano,et al. Changes in quality of life and lower urinary tract symptoms over time in cancer patients after a total prostatectomy: systematic review and meta-analysis , 2021, Supportive Care in Cancer.
[3] B. Frizzell,et al. Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy. , 2021, Brachytherapy.
[4] T. Shiraishi,et al. Radiotherapy for elder patients aged ≥80 with clinically localized prostate cancer – Brachytherapy enhanced late GU toxicity especially in elderly , 2020, Clinical and Translational Radiation Oncology.
[5] M. Matsuo,et al. Assessment of long-term changes in lower urinary tract symptoms in patients with prostate cancer who underwent low-dose-rate prostate brachytherapy. , 2020, Urology.
[6] M. Hasegawa,et al. Low‐dose‐rate brachytherapy for prostate cancer: A 15‐year experience in Japan , 2020, International journal of urology : official journal of the Japanese Urological Association.
[7] N. Katayama,et al. Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS). , 2019, Brachytherapy.
[8] P. Heathcote,et al. Improved lower urinary tract symptoms after robot‐assisted radical prostatectomy: implications for survivorship, treatment selection and patient counselling , 2019, BJU international.
[9] T. Sugihara,et al. Longitudinal change of comprehensive lower urinary tract symptoms and various types of urinary incontinence during robot‐assisted radical prostatectomy , 2019, Neurourology and urodynamics.
[10] S. Anai,et al. Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer , 2018, Clinical and translational radiation oncology.
[11] S. Anai,et al. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute , 2017, BMC Urology.
[12] N. Shigematsu,et al. Quantitative analysis of genitourinary toxicity after iodine-125 brachytherapy for localized prostate cancer: Followup of the International Prostate Symptom Score and Overactive Bladder Symptom Score. , 2017, Brachytherapy.
[13] R. Saskin,et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology.
[14] Yu-hua Lin,et al. Lower urinary tract symptoms of prostate cancer patients undergoing treatments over eight-month follow-up. , 2015, Journal of clinical nursing.
[15] S. Anai,et al. Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy , 2013, Radiation oncology.
[16] W. J. Morris,et al. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up. , 2009, International journal of radiation oncology, biology, physics.
[17] Howard Pai,et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. , 2009, International journal of radiation oncology, biology, physics.
[18] N. Shigematsu,et al. Comparison of intraoperative ultrasound with postimplant computed tomography--dosimetric values at Day 1 and Day 30 after prostate brachytherapy. , 2007, Brachytherapy.
[19] G. Pond,et al. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. , 2007, Brachytherapy.
[20] R. Stock,et al. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. , 2007, Urology.
[21] R. Stock,et al. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation , 2006, BJU international.
[22] Y. Homma,et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. , 2006, Urology.
[23] Paul Schellhammer,et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.
[24] J. Battermann,et al. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. , 2005, International journal of radiation oncology, biology, physics.
[25] A. Renshaw,et al. Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .
[26] M. Barry,et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.
[27] R. Stock,et al. Factors influencing urinary symptoms 10 years after permanent prostate seed implantation. , 2012, The Journal of urology.